KEDI U.S. Medical AI Index
The index consists of U.S.-listed equities that are highly related to medical AI.
Sentiment Summary
Recent Events
Generate Biomedicines will release its next earnings report on June 03, 2026, scheduled. Earnings releases for clinical-stage biotechnology companies typically result in price volatility exceeding 10%.
Annual Meeting of Stockholders is scheduled to be held virtually. Procedural meetings typically have minimal market impact, scheduled.
NVIDIA is scheduled to report its financial results for the first quarter of fiscal year 2027 on May 20, 2026, after the market closes; high impact (>=10%) expected as quarterly results are key performance indicators scheduled.
Tempus AI's Q1 2026 earnings release is expected. Quarterly results are significant for monitoring growth trends, expected.
First quarter 2026 financial results and business update scheduled.
The FDA's Oncologic Drugs Advisory Committee (ODAC) is scheduled to review two of AstraZeneca's oncology applications on April 30, 2026; medium importance estimated due to 5% price impact, scheduled
Eli Lilly is scheduled to report Q1 2026 earnings on April 30, 2026 scheduled.
AstraZeneca is scheduled to release its Q1 2026 earnings results on April 29, 2026, before the market opens; high importance estimated due to potential for 10% price impact, scheduled
AbbVie will announce its first-quarter 2026 financial results on April 29, 2026, before the market opens; Medium importance estimated due to historical price volatility around earnings releases, scheduled.
Alphabet is scheduled to report first-quarter 2026 financial results and hold its conference call on 2026-04-29, a near-term earnings catalyst scheduled.
First quarter 2026 earnings release and conference call scheduled for April 21, 2026. Analysts forecast EPS of $1.63, a 15.6% increase year-over-year. Estimated price impact of 5% as earnings typically drive volatility. scheduled
Presentation of six oncology studies at the American Association for Cancer Research (AACR) Annual Meeting scheduled for April 17, 2026. Low importance as conference presentations typically result in <5% price impact.
Quarterly dividend of $1.73 per share with the ex-dividend date on April 15, 2026; Low importance estimated as dividend amounts are typically anticipated by the market, scheduled.
Tempus AI announced an expanded, multi-year strategic collaboration with Gilead Sciences to advance Gilead's oncology R&D pipeline. Strategic partnerships with major pharmaceutical firms typically drive significant long-term value, scheduled.
The FDA is expected to approve the first generic versions of AstraZeneca's Farxiga (dapagliflozin) tablets on April 8, 2026; medium importance estimated due to 5% price impact from competition, scheduled
AbbVie announced on April 8, 2026 that it filed a lawsuit against the U.S. government to narrow the eligibility criteria for the 340B drug discount program.
Launch of an AI-driven molecular insight for non-small cell lung cancer (NSCLC) treatment paths scheduled for April 8, 2026. Low importance as product launches typically result in <5% price impact.